Last edition
News about "Sanofi"
Sanofi Announces Euro 1 Billion Share Buyback Programme for 2026
R&D-driven biopharma major Sanofi to repurchase shares worth up to Euro 1 billion between February and December 2026, reinforcing its capital allocation strategy and long-term growth outlook.
Sanofi | 04/02/2026 | By News Bureau
EU recommends Rezurock for CHMP approval to treat chronic GVHD
The CHMP’s positive opinion, backed by clinical trial data and real-world evidence, paves the way for Rezurock’s potential approval in the EU as a new treatment option for adult and paediatric patients aged 12 years and above with late-line chronic graft-vs-host disease.
Sanofi | 02/02/2026 | By News Bureau
Sanofi Warns of Near-Term Weakness in US Vaccine Demand Amid Antivax Rhetoric
French pharmaceutical company Sanofi expects near-term weakness in vaccine sales in the United States, attributing the anticipated softness to growing scepticism around immunizations that the company says has been fueled by misinformation.
Sanofi | 15/01/2026 | By Darshana | 136
US FDA Advances Review of Tzield in Young Children
The FDA has accepted Sanofi’s sBLA for Tzield under priority review, seeking broader pediatric use in delaying type 1 diabetes onset.
Sanofi | 06/01/2026 | By News Bureau
Tiziana Submits Annual Safety Report for Intranasal Foralumab to FDA
Tiziana has submitted its annual safety report for intranasal foralumab to the US FDA, reporting an excellent safety profile based on 37.4 cumulative patient-years of exposure and highlighting the continued need for safer therapies following the FDA’s denial of Sanofi’s tolebrutinib for non-relapsing secondary progressive multiple sclerosis.
Sanofi | 30/12/2025 | By News Bureau
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
Sanofi has agreed to acquire Dynavax, strengthening its adult immunisation portfolio with an approved hepatitis B vaccine and a shingles vaccine candidate in phase I/II development. The deal combines Dynavax’s vaccine assets with Sanofi’s global development and commercial capabilities.
Sanofi | 24/12/2025 | By News Bureau
EU Approves Sanofi's Wayrilz as First BTK Inhibitor for Immune Thrombocytopenia
Sanofi has received EU approval for Wayrilz, the first Bruton’s Tyrosine Kinase (BTK) inhibitor indicated for immune thrombocytopenia, offering a novel multi-immune modulation approach. The approval is based on positive results from LUNA 3 study, which demonstrated rapid and durable platelet responses.
Sanofi | 24/12/2025 | By News Bureau
Sanofi and Novartis have separately entered into agreements with the US government to reduce medicine prices for American patients while reinforcing long-term commitments to US-based manufacturing, research and innovation, marking a coordinated push to balance affordability with sustained pharmaceutical investment.
Sanofi | 22/12/2025 | By News Bureau | 137
Sanofi's Efdoralprin Alfa Gains EU Orphan Designation for AATD Emphysema
Sanofi’s investigational restorative recombinant therapy efdoralprin alfa has received EU orphan drug designation for alpha-1 antitrypsin deficiency–related emphysema, following positive phase II head-to-head results demonstrating success across all primary and key secondary endpoints versus the current plasma-derived standard of care.
Sanofi | 20/12/2025 | By News Bureau
ADEL Signs USD 1.04 Billion Global Licensing Deal with Sanofi for Alzheimer's Drug
ADEL has signed a global licensing deal with Sanofi for its investigational Alzheimer’s therapy ADEL-Y01, valued at up to USD 1.04 billion, including a USD 80 million upfront payment, milestone payments and royalties.
Sanofi | 16/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy